Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...
These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...
Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...